Clinical Trials Logo

TP53 Gene Mutation clinical trials

View clinical trials related to TP53 Gene Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT04976439 Completed - Colorectal Cancer Clinical Trials

Patogenic Mutation in 5 Genes

Start date: May 1, 2021
Phase:
Study type: Observational

This is a pathogenic mutation profile of colorectal patients specifically in 5 genes, i.e. APC, TP53, PIK3CA, KRAS, and MLH1. Single nucleotide variants identified were synchronized with patients' characteristics.

NCT ID: NCT04541654 Recruiting - Clinical trials for Li-Fraumeni Syndrome

Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress

LiFT_UP
Start date: September 15, 2020
Phase:
Study type: Observational [Patient Registry]

The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism).

NCT ID: NCT03272633 Terminated - Clinical trials for Acute Lymphoblastic Leukemia

Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

Start date: October 26, 2020
Phase: Early Phase 1
Study type: Interventional

This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies. Transfusion of irradiated donor cells (immune cells) from relatives may cause the patient's cancer to decrease in size and may help control cancer in patients receiving a stem cell transplant.

NCT ID: NCT03149679 Terminated - Clinical trials for Colorectal Cancer Metastatic

The p53 Colorectal Cancer Trial

Start date: May 9, 2017
Phase: Phase 2
Study type: Interventional

Single center, open labeled, phase 2 clinical trial, where patients with metastatic colorectal cancer are selected for treatment with dose dense Cyclophosphamide every second week based on TP53 mutation status; i.e. only patients with TP53 mutated tumors may be included in the treatment arm.

NCT ID: NCT02432963 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Start date: June 14, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects of vaccine therapy and pembrolizumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment, that have failed prior therapy, and that cannot be removed by surgery. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving vaccine therapy together with pembrolizumab may be a better treatment in patients with solid tumors.